Already sky high after the success of its limb-girdle muscular dystrophy therapy, reported on Monday, BridgeBio’s shares rose nearly 8% more as encaleret balanced calcium levels in patients with a ...
By Padmanabhan Ananthan (Reuters) -BridgeBio Pharma's experimental drug for a rare genetic condition that causes low blood calcium met all the main and secondary goals in a late-stage study, the ...
BridgeBio's encaleret trial for autosomal dominant hypocalcemia type 1 met all goals, showing superior results. Read more ...
BridgeBio said this morning that its investigational drug succeeded in a late-stage trial of patients with autosomal dominant ...
The company reported its second late-stage study success, this time with a drug that could become a new treatment standard ...
BBP-418 hit the mark in the phase 3 FORTIFY trial by achieving a significant increase in glycosylated alpha-dystroglycan (αDG ...
Investing.com -- BridgeBio Pharma (NASDAQ:BBIO) stock surged 8% after the company announced positive Phase 3 topline results for its experimental drug encaleret in patients with autosomal dominant ...
The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints - ...
BridgeBio Pharma said on Wednesday that its experimental drug for a genetic condition that causes low blood calcium met all the main and secondary goals in a late-stage study. (Reporting by ...
Investor's Business Daily on MSN
BridgeBio Pharma Lines Up Another 'Domino' As It Nears A Record High
A second positive "domino" fell for BridgeBio stock on Wednesday after the company reported promising results for a genetic ...
BridgeBio Pharma is having a banner week, with the Bay Area company’s encaleret acing a phase 3 trial just days after another ...
Analysts estimate that BridgeBio Pharma will report an earnings per share (EPS) of $-0.82. The announcement from BridgeBio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback